Tepmetko
Tepmetko ingredients
| Active ingredient | Strength |
|---|---|
| Tepotinib Hydrochloride | 225 mg/1 |
What Tepmetko is used for
The FDA lists the approved uses on the official label (below). In the EU, tepotinib is approved as Tepmetko for:
Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Tepmetko
- Generic name
- Tepotinib hydrochloride
- Made by
- EMD Serono, Inc.
- Forms
- Tablet
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA214096
- On the US market since
- 2021
Official information
- Tepmetko prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Tepotinib hydrochloride)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tepmetko?
Tepmetko (Tepotinib hydrochloride) is a cancer medicine made by EMD Serono, Inc., approved by the US FDA.
What are the ingredients of Tepmetko?
Tepmetko contains Tepotinib Hydrochloride (225 mg/1).
Is Tepmetko approved in Europe?
The same active substance is approved in the EU as Tepmetko.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA